EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT OF DIARRHEA CAUSED BY ENTAMOEBA-HISTOLYTICA

被引：4

作者：

COOPERSTOCK, M

DUPONT, HL

CORRADO, ML

FEKETY, R

MURRAY, DM

机构：

[1] UNIV TEXAS,SCH MED,HLTH SCI CTR HOUSTON,CTR INFECT DIS,6431 FANNIN,1 728 JFB,HOUSTON,TX 77030

[2] UNIV TEXAS,SCH PUBL HLTH,HOUSTON,TX 77025

[3] UNIV MISSOURI,MED CTR,SCH MED,DEPT PEDIAT,COLUMBIA,MO 65201

[4] ROBERT WOOD JOHNSON PHARMACEUT INST,DIV ANTIINFECT,RARITAN,NJ

[5] PROCTER & GAMBLE CO,GEN OFF HLTH CARE,CINCINNATI,OH 45239

[6] UNIV MICHIGAN,MED CTR,DIV INFECT DIS,ANN ARBOR,MI 48109

来源：

CLINICAL INFECTIOUS DISEASES | 1992年 / 15卷

关键词：

D O I：

10.1093/clind/15.Supplement_1.S254

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Entamoeba histolytica causes colonic infection that ranges from asymptomatic carriage to invasive disease with infection of extraintestinal organs, particularly the liver. The disease occurs in both sporadic and epidemic forms. Diagnosis requires visualization of trophozoites or cysts by microscopic examination of stool, colonic scrapings, or biopsy specimens. Patients with either asymptomatic or symptomatic disease may be eligible for clinical trials. A prospective, randomized, double-blind, placebo-controlled study design is recommended for asymptomatic carriers and an active-concurrent-control study design for symptomatic patients. Final outcome should be assessed 48 hours to 7 days after completion of therapy. Assessment of microbiological outcome is paramount.

引用

页码：S254 / S258

页数：5